Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP). NXL103 is a novel oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin, macrolide and quinolone resistant strains.

The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this novel oral antibacterial as a treatment for mild to moderate CAP. The study recruited 300 adult patients in 9 countries in both the Northern and Southern hemispheres. Patients were randomised (1:1:1) to three treatment arms: 500mg of NXL103 twice a day, 600mg NXL103 twice a day or 1,000 mg of amoxicillin three times a day for 7 days. The key endpoints of the study were the clinical outcome in the clinically evaluable population at the early follow-up visit (7 to 14 days post-therapy) and safety. In this study, both doses of NXL103 were effective, with clinical response rates similar to those seen in the amoxicillin group. For the primary efficacy analysis, response rates were 91.4% in the 500mg NXL103 group; 94.7% in the 600mg NXL103 group; and 88.5% in the amoxicillin group. NXL103 was generally well tolerated with the most frequent adverse events related to gastrointestinal intolerance. There were no serious drug-related adverse events reported in the study.

The complete results from this Phase II trial will be published in the first half of 2009.

NXL103 has a spectrum of activity that indicates it has the potential to be effective in the treatment of skin and skin structure infections, includi
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/29/2015)... Denmark , July 29, 2015  Ascendis Pharma ... company that applies its innovative TransCon technology to address ... host a conference call on July 30, 2015, at ... from a Phase 2 pediatric study of once-weekly TransCon ... of the top-line results before the market opens on ...
(Date:7/29/2015)... , July 29, 2015 Unilife ... a developer, manufacturer and supplier of injectable drug ... Imperium™ platform of instant patch pumps for insulin. ... multi-day wearable insulin pump that does not require ... is prefilled and pre-assembled like an insulin pen, ...
Breaking Medicine Technology:Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4
...  Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing ... Enterprises, LLC for the continued development of anti-cancer ... class of molecules called immunocytokines that are being ... cancer.  Immunocytokines, combine the immune stimulating features of ...
... 22, 2011   Marken announced today that Steve Roese ... organization, which will support Marken,s continued investment in their ... world.  Marken is now accelerating construction of several new depot ... existing locations in Singapore , Mexico and ...
Cached Medicine Technology:Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2Marken Appoints New Head of Global Quality Assurance 2
(Date:7/30/2015)... ... , ... New research finds some distinct differences in the way mesothelioma behaves ... Surviving Mesothelioma website. , Researchers with the National Institutes of Health, the FDA, ... mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) occurred in ...
(Date:7/30/2015)... ... July 30, 2015 , ... Political unrest is ... according to a new survey by leading international insurance provider Clements Worldwide. The ... medical expenses represented the largest sources of financial losses among respondents. , Twenty-eight ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading provider of ... that it is hosting a free webinar detailing the 2016 proposed rule from CMS ... and former Vice President of Regulatory Affairs for the National Association for Home Care ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... manufacturing and packaging services for consumer brands, recently completed a consolidation of all ... MD. Previously, the company operated out of two separate locations situated 11 miles ...
(Date:7/29/2015)... ... 2015 , ... Macro Wealth Management (MWM) Presidents have increased the ... program by encouraging their clients to donate their MWM planning fees to the Foundation. ... and Tim Streid, who see charitable giving as an important part of financial planning ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... avoid hospitalization by using special technology provided by the ... to a recent study. "The study showed that ... improves patients, access to care and is easy to ...
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... definitive, 3-year distribution agreement with Alliance Lithomobile, a Division ... This agreement supersedes the interim agreement announced on November ...
... Only 17 percent of Spanish-speaking women of childbearing age ... folic acid daily, according to the first- nationally representative ... , Folic acid can prevent neural tube defects ... such as spina bifida and anencephaly, which are more ...
... Jan. 5 Cambrex Corporation (NYSE: ... M. Klosk, President and Chief Executive Officer, will ... January 13, 2009 at 9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live ...
... new study reveals that the metadherin gene (MTDH) plays ... chemotherapy. The research, published by Cell Press in the ... , identifies MTDH as a promising therapeutic target for ... resist currently available therapeutic regimens and succumb to recurrent ...
... to help healthcare providers put a cap on ... Corporation ( MSC ) will introduce a new ... all healthcare team members who care for hospital ... on medical simulation , the International Meeting ...
Cached Medicine News:Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 3Health News:Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says 2Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: